Wednesday, May 6, 2009
9:00 a.m. EDT
1-800-814-4860
Webcast: http://www.nucryst.com/web_casts.htm
CALGARY,
The briefing, via conference call, is set for
The briefing will be recorded and available for re-broadcast on demand for seven days by dialing 1-877-289-8525. Callers will need to provide the operator with the following reservation number: 21305201 followed by the number sign. An audio file of the call will also be archived on the NUCRYST web site.
About NUCRYST Pharmaceuticals
NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care coating products to Smith & Nephew plc, which markets these products in over 30 countries under their Acticoat(TM) trademark. NUCRYST has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101, for use in medical devices and as an active pharmaceutical ingredient.
Acticoat(TM) is a trademark of Smith & Nephew plc SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
SOURCE NUCRYST Pharmaceuticals Corp.